About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
EYEG - Eyegate Pharmaceutic...| Previous Close | $6.33 | Open | $6.28 |
| Volume | 86.5K | Market Cap | 29.29M |
| Yield | Last Dividend |
| Armistice Capital, Llc Purchases 1,531,1... | 01/12/21 |
| EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) Director Armistice Capital, Llc bought 1,531,101 shares of the business???s stock in a transaction on Wedn... | |
| EyeGate Pharma Reports Third Quarter 202... | 11/09/20 |
| WALTHAM, MA / ACCESSWIRE / November 9, 2020 / EyeGate Pharmaceuticals, Inc. | |
| Eyegate Pharmaceuticals (NASDAQ:EYEG) St... | 10/22/20 |
| Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of... | |
| Eyegate Pharmaceuticals (NASDAQ:EYEG) Sh... | 10/20/20 |
| Eyegate Pharmaceuticals Inc (NASDAQ:EYEG)???s stock price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day m... | |
| EyeGate Pharmaceuticals : Pharma Confirm... | 08/12/20 |
| EyeGate Pharmaceuticals, Inc. , a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has... | |
| EyeGate Pharmaceuticals : August 6, 2020... | 08/06/20 |
| WALTHAM, MA, August 6, 2020 - EyeGate Pharmaceuticals, Inc. , a clinical-stage company focused on developing products for treating disorders of the ey... | |
| EyeGate Pharma to proceed its lead produ... | 07/14/20 |
| The FDA has signed off on filing of an Investigational Device Exemption (IDE) application to commence pivotal study of EyeGate Pharmaceuticals's (EYEG... | |
| EyeGate Pharmaceuticals : March 4, 2020 ... | 03/04/20 |
| WALTHAM, MA, March 4, 2020 - EyeGate Pharmaceuticals, Inc. , a clinical-stage company focused on developing products for treating disorders of the eye... | |
| EyeGate Pharmaceuticals : December 31, 2... | 12/31/19 |
| EyeGate Pharmaceuticals, Inc. , a clinical-stage company focused on developing products for treating disorders of the eye, today announced that it has... | |
| EyeGate Pharma (EYEG) Has Caught Investo... | 12/31/19 |
| Shares of EyeGate Pharmaceuticals Inc. (EYEG), which closed at a new 52-week high of $12.20 on Monday, have gained an impressive 312% in the last thre... | |
| EyeGate Pharmaceuticals : December 17, 2... | 12/17/19 |
| EyeGate Pharmaceuticals, Inc. announced today that it has received approximately $1.9 million from the exercise of warrants subsequent to the release ... | |
| EyeGate Pharma Receives $1.9 Million fro... | 12/17/19 |
| The Company is currently evaluating several strategic options in order to determine the best path forward. Following the receipt of warrant exercise p... | |
| EyeGate Pharma Announces Additional Posi... | 12/02/19 |
| As previously announced, the results of this pivotal study demonstrated statistically significant improvement in corneal re-epithelialization in patie... | |
| EyeGate shares jump on data for eye trea... | 11/22/19 |
| Shares of EyeGate Pharmaceuticals Inc. rallied 95% in premarket trading on the news that the company's experimental eye-drop bandage performed better ... | |
| EyeGate Pharma Receives Positive Nasdaq ... | 05/14/19 |
| WALTHAM, MA / ACCESSWIRE / May 14, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company") today announced that the Nasdaq Hearings P... | |
| Eyegate Pharmaceuticals beats by $0.06 | 05/08/19 |
| No summary available. | |
| EyeGate files for $50M mixed shelf | 05/03/19 |
| EyeGate Pharmaceuticals (EYEG) has filed a preliminary prospectus for a $50M mixed shelf offering. | |
| The Daily Biotech Pulse: FDA Nod For San... | 05/02/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Al... | |
| EyeGate Files IDE with FDA for PRK Pivot... | 05/02/19 |
| WALTHAM, MA / ACCESSWIRE / May 2, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (''EyeGate'' or ''the Company'') announced today it has successfully sub... | |
| EyeGate confirms path to de novo filing ... | 03/26/19 |
| No summary available. | |
| EyeGate Confirms Path to De Novo Filing ... | 03/26/19 |
| WALTHAM, MA / ACCESSWIRE / March 26, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or "the Company") has met with the U.S. Food and Drug Admi... | |
| EyeGate Pharma books $1.7M in revenue in... | 03/01/19 |
| No summary available. | |
| Eyegate Pharmaceuticals reports FY resul... | 03/01/19 |
| No summary available. | |
| EyeGate Pharma to meet with FDA | 01/16/19 |
| No summary available. | |
| EyeGate Pharma to meet with FDA | 01/16/19 |
| No summary available. | |
| Buy rating | 11/12/20 |
| HC Wainwright & Co. maintains Buy rating and lowers Price Target from $12.00 to $10.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Tech Trades | Tech Trades | 81.00 % | Follow |
| Mojo Day Trading | ProTrader Mike | 46.00 % | Subscribe |
| Biotechnology | Robert Gadimian | 26.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
